Bryan Day, PhD

Dr. Bryan Day is an internationally acclaimed cancer biologist and a foremost authority in the molecular characterization and targeted treatment of adult and pediatric brain cancers. Based at the QIMR Berghofer Medical Research Institute in Brisbane, Australia, Dr. Day leads the Sid Faithfull Brain Cancer Laboratory and serves as Co-Director of the Children’s Brain Cancer Centre. His research team focuses tirelessly on unraveling the complex biology of glioblastoma (GBM) and other aggressive neurological malignancies. His pioneering work has significantly advanced the global understanding of the tumor microenvironment, cellular heterogeneity, and the sophisticated signaling networks that enable brain tumors to evade standard therapies. A cornerstone of Dr. Day’s research involves the extensive development and utilization of patient-derived cell lines and advanced pre-clinical models, which are critical for the accurate evaluation of novel therapeutics. He is particularly renowned for his translational research identifying unique cell surface receptors as viable targets for therapeutic intervention. By leveraging these discoveries, his laboratory actively develops and tests innovative therapies and small-molecule inhibitors designed to selectively eradicate tumor cells. Dr. Day earned his PhD from the University of Queensland and has since cultivated a prolific academic career, heavily supported by prestigious grants and recognized through numerous international speaking invitations and peer-reviewed publications. In his role as a Scientific Advisor to Curtana Pharmaceuticals, Dr. Day brings exceptional proficiency in pre-clinical modeling and target validation. His rigorous, patient-centric approach to translational science empowers Curtana to accelerate the development of precision medicines, ensuring that novel compounds are meticulously vetted against the most accurate and predictive models of human brain cancer.